GE Healthcare Technologies Inc (L0T) Stock Forecast & Price Target

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

L0T Analyst Ratings

Moderate Buy

8 Buy

7 Hold

0 Sell

Based on 15 analysts giving stock ratings to

Healthcare Technologies Inc

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

L0T Stock 12 Month Forecast

Average Price Target

€67.88

▲(6.14% Upside)

Based on 15 Wall Street analysts offering 12 month price targets for GE Healthcare Technologies Inc in the last 3 months. The average price target is €67.88 with a high forecast of €78.97 and a low forecast of €57.03. The average price target represents a 6.14% change from the last price of €63.95.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"50":"€50","79":"€79","57.25":"€57.3","64.5":"€64.5","71.75":"€71.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":78.97050540000001,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€78.97</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":67.87702964142858,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€67.88</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":57.0342539,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€57.03</span>\n  </div></div>","useHTML":true}}],"tickPositions":[50,57.25,64.5,71.75,79],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,57.18,58.85619272307692,60.532385446153846,62.20857816923077,63.88477089230769,65.56096361538462,67.23715633846155,68.91334906153847,70.58954178461539,72.26573450769231,73.94192723076924,75.61811995384616,77.29431267692308,{"y":78.97050540000001,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,57.18,58.002848433956046,58.825696867912086,59.64854530186813,60.47139373582418,61.29424216978022,62.117090603736266,62.93993903769231,63.76278747164835,64.5856359056044,65.40848433956045,66.23133277351648,67.05418120747254,{"y":67.87702964142858,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,57.18,57.16878876153846,57.157577523076924,57.14636628461538,57.13515504615385,57.12394380769231,57.11273256923077,57.10152133076923,57.090310092307696,57.079098853846155,57.06788761538462,57.05667637692308,57.045465138461545,{"y":57.0342539,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":64.712,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.308,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.176,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.813,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.392,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.639,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.017,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.976,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.686,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.319,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.06,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.91,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.18,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€78.97

Average Price Target€67.88

Lowest Price Target€57.03

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Ryan Zimmerman

BTIG

€70.2→€65.81

Buy

2.91%

Upside

Assigned

07/13/26

GE HealthCare price target lowered to $75 from $80 at BTIGGE HealthCare price target lowered to $75 from $80 at BTIG

Vik Chopra

Wells Fargo

€61.42

Hold

-3.95%

Downside

Initiated

07/09/26

Analyst Maintains Hold on GE HealthCare as Innovation Upside Remains Back-End Loaded Amid Near-Term Macro and Execution Risks

Matthew Taylor

Jefferies

€78.97

Buy

23.49%

Upside

Reiterated

07/08/26

GE Healthcare Technologies Inc (GEHC) Gets a Buy from Jefferies

Joanne Wuensch

Citi

€57.03→€60.54

Hold

-5.33%

Downside

Reiterated

07/08/26

Citi adds 'upside 90-day catalyst watch' on GE HealthCareCiti adds 'upside 90-day catalyst watch' on GE HealthCare

Shagun Singh Chadha

RBC Capital

€70.2

Buy

9.77%

Upside

Initiated

06/23/26

GE HealthCare initiated with an Outperform at RBC CapitalGE HealthCare initiated with an Outperform at RBC Capital

Travis Steed

Bank of America Securities

€64.93

Hold

1.53%

Upside

Reiterated

06/12/26

GE Healthcare Technologies Inc (GEHC) Receives a Hold from Bank of America Securities

Graham Doyle

UBS

€65.81→€60.54

Hold

-5.33%

Downside

Upgraded

05/21/26

GE Healthcare Downgraded to Hold as Risk‑Reward Seen Balanced After 30% Share Slide and Lower‑Than‑Consensus EPS Outlook

Anthony Petrone

Mizuho Securities

€78.97→€70.2

Buy

9.77%

Upside

Reiterated

04/30/26

Mizuho Securities Remains a Buy on GE Healthcare Technologies Inc (GEHC)

Suraj Kalia

Oppenheimer

€78.09→€74.58

Buy

16.63%

Upside

Assigned

04/30/26

GE HealthCare price target lowered to $85 from $89 at OppenheimerGE HealthCare price target lowered to $85 from $89 at Oppenheimer

Robbie Marcus

J.P. Morgan

€70.2→€57.03

Hold

-10.81%

Downside

Reiterated

04/30/26

GE HealthCare price target lowered to $65 from $80 at JPMorganGE HealthCare price target lowered to $65 from $80 at JPMorgan

Vijay Kumar

Evercore ISI

€74.58→€70.2

Buy

9.77%

Upside

Reiterated

04/30/26

GE HealthCare price target lowered to $80 from $85 at Evercore ISIGE HealthCare price target lowered to $80 from $85 at Evercore ISI

Matt Miksic

Barclays

€76.34→€68.44

Hold

7.02%

Upside

Reiterated

04/30/26

Analysts Offer Insights on Healthcare Companies: Hinge Health, Inc. Class A (NYSE: HNGE), Ionis Pharmaceuticals (NASDAQ: IONS) and GE Healthcare Technologies Inc (NASDAQ: GEHC)

David Roman

Goldman Sachs

―

Hold

―

Downgraded

04/30/26

Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (NYSE: TEVA), GE Healthcare Technologies Inc (NASDAQ: GEHC) and Crescent Biopharma (NASDAQ: CBIO)

Rick Wise

Stifel Nicolaus

€85.99→€70.2

Buy

9.77%

Upside

Reiterated

04/29/26

GE HealthCare price target lowered to $80 from $98 at StifelGE HealthCare price target lowered to $80 from $98 at Stifel

Jason Bednar

Piper Sandler

€82.48→€77.22

Buy

20.74%

Upside

Reiterated

04/17/26

Analysts Offer Insights on Healthcare Companies: GE Healthcare Technologies Inc (NASDAQ: GEHC), Immunome (NASDAQ: IMNM) and Eli Lilly & Co (NYSE: LLY)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Ryan Zimmerman

BTIG

€70.2→€65.81

Buy

2.91%

Upside

Assigned

07/13/26

GE HealthCare price target lowered to $75 from $80 at BTIGGE HealthCare price target lowered to $75 from $80 at BTIG

Vik Chopra

Wells Fargo

€61.42

Hold

-3.95%

Downside

Initiated

07/09/26

Analyst Maintains Hold on GE HealthCare as Innovation Upside Remains Back-End Loaded Amid Near-Term Macro and Execution Risks

Matthew Taylor

Jefferies

€78.97

Buy

23.49%

Upside

Reiterated

07/08/26

GE Healthcare Technologies Inc (GEHC) Gets a Buy from Jefferies

Joanne Wuensch

Citi

€57.03→€60.54

Hold

-5.33%

Downside

Reiterated

07/08/26

Citi adds 'upside 90-day catalyst watch' on GE HealthCareCiti adds 'upside 90-day catalyst watch' on GE HealthCare

Shagun Singh Chadha

RBC Capital

€70.2

Buy

9.77%

Upside

Initiated

06/23/26

GE HealthCare initiated with an Outperform at RBC CapitalGE HealthCare initiated with an Outperform at RBC Capital

Travis Steed

Bank of America Securities

€64.93

Hold

1.53%

Upside

Reiterated

06/12/26

GE Healthcare Technologies Inc (GEHC) Receives a Hold from Bank of America Securities

Graham Doyle

UBS

€65.81→€60.54

Hold

-5.33%

Downside

Upgraded

05/21/26

GE Healthcare Downgraded to Hold as Risk‑Reward Seen Balanced After 30% Share Slide and Lower‑Than‑Consensus EPS Outlook

Anthony Petrone

Mizuho Securities

€78.97→€70.2

Buy

9.77%

Upside

Reiterated

04/30/26

Mizuho Securities Remains a Buy on GE Healthcare Technologies Inc (GEHC)

Suraj Kalia

Oppenheimer

€78.09→€74.58

Buy

16.63%

Upside

Assigned

04/30/26

GE HealthCare price target lowered to $85 from $89 at OppenheimerGE HealthCare price target lowered to $85 from $89 at Oppenheimer

Robbie Marcus

J.P. Morgan

€70.2→€57.03

Hold

-10.81%

Downside

Reiterated

04/30/26

GE HealthCare price target lowered to $65 from $80 at JPMorganGE HealthCare price target lowered to $65 from $80 at JPMorgan

Vijay Kumar

Evercore ISI

€74.58→€70.2

Buy

9.77%

Upside

Reiterated

04/30/26

GE HealthCare price target lowered to $80 from $85 at Evercore ISIGE HealthCare price target lowered to $80 from $85 at Evercore ISI

Matt Miksic

Barclays

€76.34→€68.44

Hold

7.02%

Upside

Reiterated

04/30/26

Analysts Offer Insights on Healthcare Companies: Hinge Health, Inc. Class A (NYSE: HNGE), Ionis Pharmaceuticals (NASDAQ: IONS) and GE Healthcare Technologies Inc (NASDAQ: GEHC)

David Roman

Goldman Sachs

―

Hold

―

Downgraded

04/30/26

Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (NYSE: TEVA), GE Healthcare Technologies Inc (NASDAQ: GEHC) and Crescent Biopharma (NASDAQ: CBIO)

Rick Wise

Stifel Nicolaus

€85.99→€70.2

Buy

9.77%

Upside

Reiterated

04/29/26

GE HealthCare price target lowered to $80 from $98 at StifelGE HealthCare price target lowered to $80 from $98 at Stifel

Jason Bednar

Piper Sandler

€82.48→€77.22

Buy

20.74%

Upside

Reiterated

04/17/26

Analysts Offer Insights on Healthcare Companies: GE Healthcare Technologies Inc (NASDAQ: GEHC), Immunome (NASDAQ: IMNM) and Eli Lilly & Co (NYSE: LLY)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

BBOTBridgeBio Oncology Therapeutics

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

MLYSMineralys Therapeutics, Inc.

AMLXAmylyx Pharmaceuticals Inc

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering GE Healthcare Technologies Inc

3 Months

Larry BiegelsenWells Fargo

Success Rate

12/21 ratings generated profit

Average Return

+0.25%

Copying Larry Biegelsen's trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +0.25% per trade.

1 Year

Anthony PetroneMizuho Securities

Success Rate

6/15 ratings generated profit

Average Return

-0.75%

Copying Anthony Petrone's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -0.75% per trade.

2 Years

Larry BiegelsenWells Fargo

Success Rate

6/21 ratings generated profit

Average Return

-10.32%

Copying Larry Biegelsen's trades and holding each position for 2 Years would result in 28.57% of your transactions generating a profit, with an average return of -10.32% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

L0T Analyst Recommendation Trends

Rating

Mar 26

Apr 26

May 26

Jun 26

Jul 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, L0T has received 4 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. L0T average Analyst price target in the past 3 months is 67.88.

Each month's total comprises the sum of three months' worth of ratings.

L0T Financial Forecast

L0T Earnings Forecast

Next quarter’s earnings estimate for L0T is €0.91 with a range of €0.89 to €0.92. The previous quarter’s EPS was €0.87. L0T beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year L0T has Performed in-line its overall industry.

L0T Sales Forecast

Next quarter’s sales forecast for L0T is €4.63B with a range of €4.55B to €4.67B. The previous quarter’s sales results were €4.50B. L0T beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year L0T has Performed in-line its overall industry.

L0T Stock Forecast FAQ

What is DE:L0T’s average 12-month price target, according to analysts?

Based on analyst ratings, Ge Healthcare Technologies Inc.’s 12-month average price target is 67.88.

What is DE:L0T’s upside potential, based on the analysts’ average price target?

Ge Healthcare Technologies Inc. has 6.14% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Ge Healthcare Technologies Inc. a Buy, Sell or Hold?

Ge Healthcare Technologies Inc. has a consensus rating of Moderate Buy, which is based on 8 buy ratings, 7 hold ratings and 0 sell ratings.

What is Ge Healthcare Technologies Inc.’s share price target?

The average share price target for Ge Healthcare Technologies Inc. is 67.88. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €78.97 ,and the lowest forecast is €57.03. The average share price target represents 6.14% Increase from the current price of €63.95.

What do analysts say about Ge Healthcare Technologies Inc.?

Ge Healthcare Technologies Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 15 Wall Streets Analysts.

How can I buy shares of Ge Healthcare Technologies Inc.?

To buy shares of DE:L0T, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

GE Healthcare Technologies Inc (L0T) Stock Forecast & Price Target

L0T Analyst Ratings

L0T Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering GE Healthcare Technologies Inc

L0T Analyst Recommendation Trends

L0T Financial Forecast

L0T Earnings Forecast

L0T Sales Forecast

L0T Stock Forecast FAQ

Detailed List of Analyst Forecasts